Legalizing Marijuana Would Calm CBD Regulatory Storm – CV Sciences' MacKay
As FDA moves slow on allowing CBD as a dietary ingredient, a marijuana reform law is a near-term possibility and would cause a “nuclear shift” about cannabis regulation and sway agency's decision, says cannabidiol firm CV Sciences executive.
You may also be interested in...
Agency seeks comment, at May 31 public hearing and docket open through July 2, on health and safety risks, manufacturing and product quality and marketing/labeling/sales around allowing cannabis-derived ingredients non-drug products. It wants input from across sectors of stakeholders, including opponents as well as proponents of allowing cannabis-derived ingredients in any category of regulated products other than drugs.
A consultant on behalf of CBD product marketer Wildflower Brands was put on the spot at the agency’s May 31 public hearing when asked what the company views as the functional purpose of CBD in beauty offerings.
Legal dispute between FDA and Pharmanex decided in 1999 could be precedent for using hemp-derived ingredients including CBD in supplements, even though CBD already has been authorized for clinical drug evaluation and for use in a drug, says attorney Miriam Guggenheim.